Analyst Yaron Werber from TD Cowen maintained a Buy rating on Ionis Pharmaceuticals and increased the price target to $99.00 from $59.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yaron Werber has given his Buy rating due to a combination of factors that highlight Ionis Pharmaceuticals’ strong growth potential and strategic advancements. The company has shown impressive performance in the third quarter, particularly with the success of Tryngolza, which exceeded expectations and suggests a larger market opportunity for familial chylomicronemia syndrome (FCS) than initially anticipated. This success is expected to drive significant growth, especially with the upcoming launch of sHTG in the fourth quarter of 2026, marking a pivotal moment in the company’s commercial expansion.
Furthermore, Ionis is positioned for a catalyst-rich fiscal year 2026, with multiple Phase 2 and 3 data releases that could significantly impact its growth trajectory. The anticipated launch of Dawnzera in hereditary angioedema (HAE) and the potential for robust revenue growth from its late-stage cardiometabolic and neurology pipeline are key factors supporting the Buy rating. Additionally, the company’s path to profitability is bolstered by the expected breakeven point in 2028, driven by these strategic initiatives and the differentiated potential of its product candidates like Wainua for transthyretin amyloidosis and ION582 for Angelman syndrome.
According to TipRanks, Werber is a 5-star analyst with an average return of 19.7% and a 60.13% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, BioNTech SE, and Roivant Sciences.